■ Abstract
with nephrotic syndrome, the prognosis in developing countries is still poor. The increase in patients with suboptimal diabetes control and the presence of severe diabetic nephropathy in young type 1 patients present a challenge to both nephrologists and obstetricians [5] [6] [7] .
The prevalence of type 1 diabetes during pregnancy is variable world-wide and there are differences in the definition of diabetic nephropathy [8] [9] , which makes it difficult to combine epidemiological data. When diabetic nephropathy is broadly defined as the presence of any sign of renal disease including microalbuminuria, its prevalence ranges from 5% to over 25% in type 1 diabetic pregnant women. The highest prevalence is recorded in tertiary care centers owing to the obvious selection of referred patients [10] [11] [12] .
Diabetes during pregnancy has been associated with a variety of complications, including congenital malformations, fetal growth retardation, stillbirth, early mortality, and preterm delivery [13] [14] [15] [16] [17] [18] . In this context, the presence of diabetic nephropathy adds further risks. These include progression of chronic kidney disease during or after pregnancy, worsening of microvascular or macrovascular disease and increased incidence of pregnancy-related hypertensive disorders such as pregnancy-induced hypertension, pre-eclampsia (PE) or HELLP syndrome [19] [20] [21] [22] [23] [24] . The definition of hypertensive disorders may be challenging since PE features (proteinuria and hypertension after the 20th gestational week) overlap with those of diabetic nephropathy. Moreover, definitions of "superimposed PE" are non-univocal [25] [26] .
The improvements in maternal-fetal care and the increased recognition of the effects of kidney disease in pregnancy have contributed to significant changes in the risk-benefit balance of "high risk" pregnancies and changed the prognosis for preterm babies [31] [32] [33] . Furthermore, epigenetic and developmental studies have underlined the importance of early exposure to pathologic noxae in the development of adult diseases, thus raising long-term concerns about preterm, growthrestricted babies and children born of mothers affected by different disorders [34] [35] [36] [37] [38] [39] .
Despite the fact that there are several recent reviews on the changing clinical spectrum of diabetic nephropathy, no review has analyzed the outcomes of pregnancy in patients with diabetic nephropathy in type 1 diabetes [27] [28] [29] [30] . The main reason for performing the present systematic review is the need for constantly updated, evidencebased information for counseling, a pivotal task in the era of patient empowerment [40] [41] .
Methods

Search strategy
Simultaneous searches were performed in Pubmed, Embase and the Cochrane Library (in the last week of November 2012). The search was deliberately broad to increase sensitivity, according to the guidelines of the Cochrane Collaboration. Search terms included pregnancy as MESH, Emtree and free term and diabetic nephropathy as MESH and free term. The reference lists of reviews and selected papers were also searched for papers that had not been retrieved by the previous search strategy.
Selection criteria
Case series with less than 5 patients and patients with kidney or pancreas-kidney transplant were excluded. Likewise, papers dealing with longterm effects on mother and offspring (over 6 months) were not considered for the present analysis which is limited to pregnancy-related outcomes.
The limitations imposed on the selection of papers related both to patients and to time of publication (as provided by Medline). The period from 1980 to 2012 was selected because of the profound changes in diabetes care that have occurred since the early nineteen-eighties. Although the search was not limited to English, language barriers impaired the evaluation of four papers published in Japanese [42] [43] [44] [45] .
The search was performed in duplicate by GBP and RC. They worked independently and subsequently matched results. Abstracts and titles were screened by GBP, RC, and GC; controversies were resolved by discussion. The final paper selection was approved by the whole group and data were extracted in duplicate. The study group "Rene e Gravidanza" monitored the retrieved data and the final results. stillbirth/neonatal death, small for gestational age (SGA), intrauterine growth restriction (IUGR), admission to intensive care unit (NICU), malformations, other neonatal complications (whenever reported), maternal and fetal follow-up, definition of diabetic nephropathy, and inclusion criteria.
Papers were divided into three major periods: 1980-1989; 1990-1999 and 2000 to present. As the definition of PE has changed over time, the older 
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Studies included in the systematic review (n = 35) Figure 1 . Study design. In total, 818 articles have been retrieved from database screening. After removal of duplicate and nonrelevant articles, 122 have been assessed for eligibility. Of these 122 articles, reviews and further non-relevant articles have been excluded such that finally 35 studies could be included in the present study.
term "gestosis" was considered equivalent to PE. Relevant definitions (for example as for HELLP or pregnancy-induced hypertension) were also collected. The decision to perform a narrative or metaanalytical systematic review was dependent on the type and quality of the evidence retrieved. Since we were expecting to deal with a high degree of heterogeneity, a descriptive narrative review was planned for the main results and outcomes, while data pooling was envisaged for each period according to the degree of diabetic nephropathy. Data analysis was performed using SPSS version 18.0.
Results
Retrieving the evidence and summary data
Our search on diabetic nephropathy (type 1 diabetes) and pregnancy identified 209 articles from 1058 references. Thirty-four satisfied the selection criteria, one article was added from the reference lists (Figure 1 ) [12, . Sixteen studies (719 pregnancies) published in 2000-2012 (Table 1) , 15 studies (719 pregnancies) published in 1990-1999 (Table 2) , and 4 studies (73 pregnancies) published in 1980-1989 were selected ( Table 3) . Most studies were monocentric. Because case reports were not included, the number of observed patients ranged from 5 to 311. Two studies only included more than 100 pregnancies and stratified the patients according to albuminuria levels.
The studies originated from all over the world: ten were from North America, eighteen from Europe, one from Asia, one from New Zealand, one from South America and four from Israel. Overall, Europe and USA are the main sources of the data. The studies were heterogeneous with regard to duration (from 1 to over 20 years) and period of study (1966-1981 through 2010-2011) (Tables 1-3) . Seventeen studies included "controls". Of these studies, nine included type 1 pregnant diabetic patients without nephropathy as controls.
Definitions and staging of diabetic nephropathy
Most of the studies gave the definition of diabetic nephropathy or the selection criteria employed when they dealt with retrospective analyses (Tables 4-6, in the Appendix). However, the defi- . Abbreviations: Ctrls -controls, DN -diabetic nephropathy, IDDM -insulin-dependent diabetes mellitus, nnumber of pregnancies, NR -not reported, PE -pre-eclampsia, Pro -prospective, Pts -patients, Ret -retrospective. References [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] .
nitions differed over time. Diabetic nephropathy was more often defined by albumin excretion rates. The cut-off point most frequently applied since 2000 was 300 mg/day, while 500 mg/day was generally used before that date. Some studies included serum creatinine in the definition (e.g. Yogev, 2010 [76] ), while others stressed the fact that urinary albumin excretion (UAE) should be considered when bacteriuria and other signs of kidney disease (e.g. Biesenbach, 1999 [63] ) are absent or diabetic retinopathy (e.g. Bagg, 2003 [70] ) or hypertension (i.e. Schröder, 2000 [64] ) are present.
Microalbuminuria represents a "huge area", occasionally defined as "non-apparent diabetic nephropathy" (Schröder, 2000 [64] ) or included in "diabetic nephropathy" (Young, 2011 [77] ) (Tables 4-6, in the Appendix). In line with the changes in age at conception observed in the last decades, mean/median age has progressively increased in Western countries from the 20s to the 30s, in particular over the periods of 1980-1990 and 2010-2013 . This may reflect a delay in the onset of diabetic nephropathy (Tables 4-6, in the Appendix).
Diabetes control, reported at different intervals during pregnancy, is also variable as a reflection of study settings and patient selection (Tables 4-6, in the Appendix).
Main maternal outcomes
Main maternal outcomes are reported in Tables 7-9 (in the Appendix). According to the search strategy, papers containing information on shortterm pregnancy-related outcomes were included in the analysis. Five papers were mainly dealing with long-term outcomes, but also included short-term data, and were thus selected as well.
Proteinuria and hypertension are the main hallmarks of diabetic nephropathy during pregnancy. Pre-eclampsia is usually defined as proteinuria >300 mg/day, hypertension in the absence of proteinuria and pre-conception hypertension. However, the role of baseline microalbuminuria is not clear and none of the studies give any information on uteroplacental blood flows or other obstetrical or biochemical markers of PE ( Tables 7-9 , in the Appendix). The different definitions of PE may account for some of the differences recorded. PE and/or nephrotic proteinuria, considered together, are described in over 60% of cases with baseline nephropathy (for example Themeli In those papers describing different stages of diabetic nephropathy, worsening is reported as more frequent in cases where there is functional impairment or severe proteinuria at baseline (Tables 7-9, in the Appendix). However, the inhomogeneity of the definitions prevents the pooling of data. In the context of good overall glycemic control, no clear link between glycated hemoglobin and outcomes would appear to be evident in this descriptive analysis.
Notably, maternal age reported in the papers showed an increasing trend, presumably in parallel to the increase in the overall population. All the series published in the first decade include women younger than 30 years (mean or median age). In the second decade, women aged less than 30 years make up 11/15 of the patients (7 <28 years) and this figure is 10/16 in the last period (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) . In the last period, 2 series only include cases with a mean/median age <28 years.
Main fetal outcomes
The main fetal outcomes are reported in Tables [67] ) which use non-microalbuminemic patients, homogeneously defined, as controls are considered, a higher prevalence of adverse pregnancy-related events in cases with micro-and macro-albuminuria is confirmed as is also the case for SGA and preterm delivery (both at gestational age <34 and <37 weeks), although the prevalence of perinatal death and stillbirth is not higher, possibly because of the small number of cases ( Table 13) .
Caesarian section rates in microalbuminuric patients vary widely from none (Nielsen, 2009 {74] ) to about 20%. Higher levels are recorded in patients with full-blown diabetic nephropathy (up to over 90% according to Khouri 2002 [68] ). The incidence of preterm delivery is likewise high, within a wide range, and it is almost the rule in full-blown diabetic nephropathy. Again, there is an increasing trend in severe diseases (albeit differently defined) (Tables 10-12 , in the Appendix).
Against a background of risk for macrosomal babies, the incidence of SGA and IUGR increased along with worsening of kidney disease. Once more, the definitions of SGA and IUGR were nonunivocal and this may account for at least part of the reported variability (Tables 10-12 , in the Appendix). As a reflection of the different definitions and populations studied, the prevalence of preterm delivery remained high without a decreasing trend over the three decades analyzed.
It is worth noting that the incidence of stillbirth and neonatal death has remained high in recent years (5.5% according to Themeli 2012 [78] , 6% according to Yogev 2010 [76] ). However, there may be suggestions of an improving trend as compared with the cumulative incidence of neonatal and fetal death of over 10% in the eighties. The inhomogeneity of the definitions prevents further pooling of the data. In the context of overall good glycemic control, no clear link between glycated hemoglobin and outcomes would appear to be evident in this descriptive analysis. Only one paper specifically reported on malformations, described as increased in diabetic nephropathy as compared with diabetic patients (Bell, 2012 [78] ).
Discussion
The most common complications of diabetes and pregnancy affect the kidney. It is not surprising therefore that several pregnancy-related adverse outcomes, such as hypertension, proteinuria and PE, were more common in diabetic patients, and even more common in patients with diabetes and kidney disease [10] [11] [12] [13] [14] [15] [16] [17] .
In an era when patients are increasingly required to participate in therapeutic choices, a systematic review of the literature may be helpful for counseling. Thus, the present review started from the early eighties, the time when the DCCT study set new standards and goals for diabetic care [80] . The review deals with short-term pregnancyrelated outcomes, by definition within 6 months of delivery or after birth.
In our opinion, five major points emerge from our analysis which are potentially relevant to patient counseling. The first point is the relatively limited evidence available on this very important and challenging nephropathy (Tables 1-3) . In fact, out of thirty-four papers retrieved, only two reported on more than 100 patients, while most studies (28/35) described less than fifty patients (Tables 1-2) . The second point relates to the definitions of diabetic nephropathy. In fact, after the publication of the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, attention shifted to earlier stages of kidney disease, in part as a reflection of the change in the definition of chronic kidney disease, which was substantially modified in the new millennium [81] (Tables 4-6 , in the Appendix). In diabetic nephropathy, as well as in clinical nephrology, a common language is urgently required [26] . The wide range of definitions of diabetic nephropathy is likely to affect the results. In recent reports, diabetic nephropathy has in-cluded albuminuria or required urinary proteins to reach 0.5 g/day. It may or may not take serum creatinine into account or require the presence of other signs of microvascular disease (Tables 4-6 , in the Appendix).
These first two points should give rise to discussion of the limits and biases of the available evidence in the context of patient counseling. Given these limits, the third point is that, in each period of study, there was substantial agreement on a negative observation. Indeed, the risks for pregnancy-related adverse events were increased in patients with type 1 diabetes and diabetic nephropathy (Tables 1-12) .
Furthermore, there would appear to be an overall increase in risk as diabetic nephropathy progresses, following a trend similar to that observed in other kidney disease [26, 82, 83] . Maternal outcomes are widely scattered and probably reflect several factors: the lack of univocal definitions of diabetic nephropathy, chronic kidney disease, and PE, increasing maternal age over time, different study aims, patient selection and the setting of several studies, small sample size, and single-center and care setting (Tables 1-12) .
Within this framework, two further aspects may be emphasized. The risks do not decrease over time (Tables 7-9 , in the Appendix). An increase in maternal age, observed over time, and presumably paralleling the ageing of the overall population, may be one of the clues which explains part of this phenomenon, as an increase in maternal age is associated with an independent risk for adverse pregnancy-related outcomes and proteinuria. Hypertension, proteinuria and PE are the most relevant challenges; however the relative role of each complication is difficult to determine, another reflection of the non-univocal definition of PE and "superimposed PE", in particular with respect to microalbuminuria (Tables 7-9, in the Appendix). In fact, the strict definition of PE (proteinuria and hypertension after the 20th gestational week in a previously normotensive, non proteinuric patient), was designed to identify cases without kidney damage at baseline, a situation that hardly applies to patients with microvascular disease [25] .
Conversely, the risks of a worsening in kidney function are more difficult to summarize, as all possible occurrences are reported in the studies (increase, decrease, stable kidney function) and probably depend upon a complex interaction between baseline function and pregnancy-related outcomes. Furthermore, without a comparison of long-term outcomes in type 1 diabetic patients with a comparable degree of kidney disease but no pregnancies it is impossible to reach definitive conclusions (Tables 4-9 , in the Appendix). Thus, counseling on the maternal risks should underline the increased risk of developing hypertension and proteinuria, either in the context of PE or as a specific response of baseline nephropathy to the challenge presented by hyperfiltration during pregnancy. Moreover, it is important to mention the highly unpredictable but observed risk of a worsening in kidney function during pregnancy and after delivery (Tables 7-9 , in the Appendix). Remarkable differences in the reported outcomes suggested a relevant "center effect" and they are in favor of referral to experienced settings.
The last two points concern fetal outcomes. The first is related to the greatest risks of diabetic pregnancies: stillbirth or fetal death (Tables 10-12 , in the Appendix). While the high risk of prematurity and SGA or intrauterine growth restriction is also shared by patients with other kidney disorders and increases as the kidney disease progresses, stillbirth or fetal death are shared only by patients with systemic lupus erythematous, another systemic syndrome with remarkable microvascular damage [26, 82, 83] . The risk has also been reported in diabetic patients without overt nephropathy, but appears to be increased in the setting of diabetic nephropathy (Tables 10-12 , in the Appendix). Interestingly, even if the risks of stillbirth and fetal death have been reduced in the period from 2000 to date compared to the eighties (from over 10% to about 5%), the reduction is much less than that observed in the case of mothers on dialysis for example, which has decreased by 25% in each decade since the eighties, albeit starting from a much higher level [84] [85] [86] ).
The last issue touches on a very specific point: the increase in fetal malformations in diabetic nephropathy, as compared with diabetes, reported in a single recent paper [79] . The study in question, which challenges an old theory stating that the presence of kidney disease may complicate the clinical management of pregnancy but does not increase the risk of malformations, will need further confirmation. It also emphasized how much has to be studied in the field of diabetic nephropathy and pregnancy.
The limitations of systematic reviews are primarily the limitations of the current evidences. Our study therefore reflected the lack of large control groups and the high heterogeneity of the selected papers. Furthermore, as we chose to give a wide panorama of the current evidence; we did not limit our selection to the few papers with control groups or shared definitions of PE or diabetic nephropathy, thus preferring a narrative over a meta-analytical approach.
Several suggestions for future research may arise from the limits of the present review. First of all, the data available mainly reflect the European and USA standards of care, and only a few papers, in the recent period, came from developing countries (Pakistan, Brazil, Tables 1-3) . We are acutely aware of the differences in general health status and medical practice of different populations and hope that our study may revive interest and awareness resulting in the collection of more information that can be used to tailor dedicated approaches. Ideally, future papers should include homogeneous information not only on the main maternal-fetal outcomes, homogeneously defined, but also on other outcome modifiers including the following type of care (multidisciplinary versus mainly managed in the nephrology or diabetology setting), adherence to the current guidelines (specifying the guideline in question), concurrent diabetes-related comorbidity with particular emphasis on retinopathy (as a marker of microvascular disease) and obesity and cardiovascular disease with information on their independent effect on pregnancy-related outcomes.
Within these limits, our study represents the only available systematic review recently undertaken on diabetic nephropathy in pregnancy. It may be of use both in counseling, when it is important to emphasize the limits of the current evidence, and in planning future research, which is urgently needed to reduce the adverse outcomes associated with this ancient and yet mysterious disease.
Conclusions
In conclusion, evidence on diabetic nephropathy in type 1 diabetic patients during pregnancy was plentiful albeit non-homogeneous. Despite great advances in maternal-fetal care and in diabetes control, the risks for the major adverse maternalfetal outcomes have not substantially decreased over time.
Subtle changes in the populations studied may partly account for this unexpected result. The data underline the need for prospective, multicenter studies, with clearly defined outcomes and data collections, which would not only promote better understanding, but also assist in producing and updating practical algorithms on the care of pregnant women with diabetic nephropathy.
In any case, our review underlines the need for further studies to obtain better insight into the complex relationship between pre-existing and pregnancy-induced microvascular damage and the need for careful, multidisciplinary counseling, with particular attention to the uncertainties and limits of the currently available evidence.
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